ArticleThe oncologist2026
Prognostic significance of positive margin-informed tumor status in esophageal squamous cell carcinoma using next-generation sequencing.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundReliable prognostic biomarkers are urgently needed for operable esophageal squamous cell carcinoma (ESCC), as conventional histopathology often fails to detect minimal residual disease and accurately predict patient outcomes. PATIENTS AND
methodsThis study investigated the mutational patterns in ESCC and the prognostic value of shared mutations between tumors and margins (margin-informed tumor, MiT) using next-generation sequencing. We analyzed tumor, margin, and normal tissues from a total of 70 patients with operable ESCC, including 48 from a retrospective cohort and 22 from a prospective cohort.
resultsTP53 mutations were more prevalent in tumors than in margins or normal tissues (retrospective, P <.0001; prospective, P = .02), while NOTCH1 mutations were more frequent in normal or margin tissues (retrospective, P = .0002; prospective, P = .07). Positive MiT was observed in 16.7% of the retrospective cohort and 45.5% of the prospective cohort, respectively, with all patients exhibiting over 50% shared mutations experiencing disease progression. Patients with identical TP53 mutations in both tumor and margin tissues (TP53-MiT) exhibited significantly worse survival (retrospective, hazard ratio [HR] = 3.32, 95% confidence interval [CI], 1.11-9.91, P = .03; prospective, HR = 4.35, 95% CI, 0.87-21.63, P = .05). TP53 mutations were associated with tumorigenic pathways and low immune infiltration fraction.
conclusionOur findings underscore the clinical importance of MiT, particularly TP53-MiT, in postoperative prognosis. Integrating TP53-MiT assessment into postoperative evaluations could refine risk stratification and guide adjuvant management better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.